← Leaderboards
Timothy Charles Nichols
University Of North Carolina Chapel Hill
$20,287,823
Attributed
$23,351,195
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,351,195 · 7
By mechanism
R24$15,087,645 · 1
R01$6,126,744 · 3
P01$1,355,033 · 2
P60$781,773 · 1
Top collaborators
- Chengwen Li12 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Dougald M Monroe$1,892,874
- Darrel W Stafford$14,989,135
- Mark E Brecher$1,075,450
- Gilbert C. White$11,716,605
- Richard Superfine$26,866,812
Others in their field
Top investigators on “Hemophilia B”
- Mark A Kay · Stanford University$23,011,919
- Roland W. Herzog · Indiana University Indianapolis$22,320,695
- Paul K Whelton · Tulane University Of Louisiana$13,863,648
- Valder R Arruda · Children'S Hospital Of Philadelphia$12,184,170
- Andrew M Davidoff · St. Jude Children'S Research Hospital$11,301,488
- William H Velander · University Of Nebraska Lincoln$9,587,071
Research focus
Hemophilia BHemophilia ACanis FamiliarisGene TherapyBloodAntibodiesAnimal ModelHemorrhagePhenotypeGene TransferVectorAnimalsPlasmaClinical TrialsCoagulation ProcessResourcesMaintenanceTrainingResearch PersonnelFundingGrantPublicationsDoseInherited
Grant awards (43)
Novel strategy to block Nabs for AAV gene delivery$601,627
R01 · FY2025 · AI
Novel strategy to block Nabs for AAV gene delivery$617,680
R01 · FY2024 · AI
Novel strategy to block Nabs for AAV gene delivery$579,400
R01 · FY2023 · AI
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$625,580
R01 · FY2022 · HL
Novel strategy to block Nabs for AAV gene delivery$578,782
R01 · FY2022 · AI
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$627,135
R01 · FY2021 · HL
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$488,270
R01 · FY2020 · HL
Maintenance of Models of Human Hemophilia and VWD$548,660
R24 · FY2019 · HL · contact PI
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$488,270
R01 · FY2019 · HL
Maintenance of Models of Human Hemophilia and VWD$1,097,318
R24 · FY2018 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2018 · HL · contact PI
Maintenance of Models of Human Hemophilia and VWD$1,072,618
R24 · FY2017 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2017 · HL · contact PI
Maintenance of Models of Human Hemophilia and VWD$1,076,728
R24 · FY2016 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2016 · HL · contact PI
Maintenance of Models of Human Hemophilia and VWD$1,072,618
R24 · FY2015 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2015 · HL · contact PI
Maintenance of Models of Human Hemophilia and VWD$1,048,483
R24 · FY2014 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$480,792
R24 · FY2013 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$722,913
R24 · FY2012 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$729,866
R24 · FY2011 · HL · contact PI
Animal Core for Gene Therapy of Hemophilia$346,339
P01 · FY2011 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$721,047
R24 · FY2010 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$734,291
R24 · FY2009 · HL · contact PI
CORE--Canine$179,397
P01 · FY2009 · HL · contact PI
Maintenance of Animal Models of Human Hemophilia and VWD$730,361
R24 · FY2008 · HL · contact PI
CORE--Canine$173,966
P01 · FY2008 · HL · contact PI
Maintenance of Animal Models of Human Hemophillia and VWD$664,967
R24 · FY2007 · HL · contact PI
CORE--Canine$217,398
P01 · FY2007 · HL · contact PI
Maintenance of Animal Models of Human Hemophillia & vWD$666,604
R24 · FY2006 · HL · contact PI
CORE--Canine$212,652
P01 · FY2006 · HL · contact PI
Maintenance of Animal Models of Human Hemophillia &vWD$671,832
R24 · FY2005 · HL
CORE--Canine$225,281
P01 · FY2005 · HL
Maintenance of Animal Models of Human Hemophillia &vWD$655,869
R24 · FY2004 · HL
Maintenance of Animal Models of Human Hemophillia &vWD$700,129
R24 · FY2003 · HL
MAINTENANCE OF ANIMAL MODELS OF HUMAN HEMOPHILIA AND VWD$579,639
R24 · FY2002 · HL
NF-KB ACTIVATION AND ORAL INFLAMMATION IN ATHEROGENESIS$149,604
P60 · FY2002 · DE
NF-KB ACTIVATION AND ORAL INFLAMMATION IN ATHEROGENESIS$149,604
P60 · FY2002 · DE
MAINTENANCE OF ANIMAL MODELS OF HUMAN HEMOPHILIA AND VWD$564,031
R24 · FY2001 · HL
NF-KB ACTIVATION AND ORAL INFLAMMATION IN ATHEROGENESIS$149,604
P60 · FY2001 · DE
MAINTENANCE OF ANIMAL MODELS OF HUMAN HEMOPHILIA AND VWD$548,879
R24 · FY2000 · HL
NF-KB ACTIVATION AND ORAL INFLAMMATION IN ATHEROGENESIS$216,178
P60 · FY2000 · DE
NF-KB ACTIVATION AND ORAL INFLAMMATION IN ATHEROGENESIS$116,783
P60 · FY2000 · DE